For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221205:nRSE5183Ia&default-theme=true
RNS Number : 5183I Hipgnosis Songs Fund Limited 05 December 2022
LEI: 213800XJIPNDVKXMOC11
Hipgnosis Songs Fund Limited ("Hipgnosis" or the "Company")
Transaction in Own Shares
5 December 2022
Hipgnosis Songs Fund Limited announces that it has purchased 250,000 of its
ordinary shares of no par value, as detailed below:
Aggregate number of ordinary shares purchased: 250,000
Price per share: 83.40p
Trade date: 2 December 2022
Settlement date: 6 December 2022
The purchased ordinary shares will be held in treasury. Following completion
of the above transaction, the Company will have 1,209,214,286 ordinary shares
in issue (excluding shares held as treasury shares), 1,209,214,286 voting
rights and 2,000,000 ordinary shares held in treasury.
For further information please contact:
Hipgnosis Song Management
Merck Mercuriadis
Chris Helm
Giles Croot (Media) +44 (0)20 4542 1511
Rufina Pavry (Investors) +44 (0)20 4542 1530
Singer Capital Markets - Joint Corporate Broker +44 (0)20 7496 3000
James Moat / James Maxwell / Alex Emslie (Corporate Finance)
Alan Geeves / James Waterlow / Sam Greatrex (Sales)
J.P. Morgan Cazenove - Joint Corporate Broker +44 (0)20 7742 4000
William Simmonds / Jérémie Birnbaum (Corporate Finance)
James Bouverat (Sales)
RBC Capital Markets - Joint Corporate Broker +44 (0)20 7635 4000
Elliot Thomas / Max Avison (Corporate Finance)
Lisa Tugwell / Anastasia Mikhailova (Sales)
Ocorian - Company Secretary & Administrator +44 (0) 28 9693 0222
Lorna Zimny
The Outside Organisation +44 (0)7711 081 843
Alan Edwards / Nick Caley
FTI Consulting +44 (0)7771 978220; +44 (0)7809 411882; +44 (0)7761 332646
Neil Doyle / Paul Harris / Laura Ewart
All US music publicity enquiries +1 917 767 5255
Fran Defeo
Notes to Editors
About Hipgnosis Songs Fund
Hipgnosis, which was founded by Merck Mercuriadis, is a Guernsey registered
investment company established to offer investors a pure-play exposure to
songs and associated musical intellectual property rights. The Company has
raised a total of almost £1.3 billion (gross equity capital) through its
Initial Public Offering on 11 July 2018, and subsequent issues in April
2019, August 2019, October 2019, July 2020, September 2020, February
2021 and July 2021. In September 2019, Hipgnosis transferred its entire
issued share capital to the Premium listing segment of the Official List of
the FCA and to the London Stock Exchange's Premium segment of the Main
Market, and in March 2020 became a constituent of the FTSE 250
Index. Since April 2021, the Company has been resident in the UK for tax
purposes and is recognised as an investment trust under applicable HMRC
regulations.
About Hipgnosis Song Management Limited
The Hipgnosis Songs Fund's Investment Adviser is Hipgnosis Song Management
Limited, which was founded by Merck Mercuriadis, former manager of globally
successful recording artists, such as Elton John, Guns N' Roses, Morrissey,
Iron Maiden and Beyoncé, and hit songwriters such as Diane Warren, Justin
Tranter and The-Dream, and former CEO of The Sanctuary Group plc. The
Investment Adviser has assembled an Advisory Board of highly successful
music industry experts which include award winning members of the artist,
songwriter, publishing, legal, financial, recorded music and music management
communities, all with in-depth knowledge of music publishing. Members
of Hipgnosis Song Management Limited Advisory Board include Nile Rodgers,
The-Dream, Giorgio Tuinfort, Starrah, David A. Stewart, Poo Bear, Bill
Leibowitz, Ian Montone and Rodney Jerkins.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSZZLFBLLLLFBL